This site uses cookies to bring you the best experience. Find out more
Skip to main content

News

Find Out The Latest

You can keep in touch with exciting developments for The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also keep up to date by following us on Twitter or LinkedIn    


OxSonics strengthens management team with hire of Dr Marianna Lalla as Chief Medical Officer

OxSonics strengthens management team with appointment of Dr Marianna Lalla as Chief Medical Officer Underpins Company’s strategy to expand its pipeline of clinical combination studies Oxford, UK – 6th June 2022 – OxSonics Therapeutics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer, is pleased to announce that Dr Marianna Lalla has joined the Company as Chief Medical Officer (CMO).... Read more

moa raises $44m Series B to Progress a New Generation of Safe, Sustainable Crop Protection Products

Financing co-led by new investor Lansdowne Partners and existing investors Oxford Science Enterprises and Parkwalk Advisors, with BGF Investments, Bits x Bites Growth Fund, IP Group, and University of Oxford participating Investment will advance moa’s pipeline of new crop protection products designed to increase the resilience and security of the world’s food production system by tackling the urgent global problem of weed... Read more

Innovation community at TOSP expands further as companies move into the Hayakawa Building

Innovation community at The Oxford Science Park expands further as companies move into the Hayakawa Building New occupiers include CyanoCapture and Ochre Bio Oxford, UK, May 16 2022  – The innovation community at The Oxford Science Park, one of Europe’s leading locations for science and technology companies, continues to expand as firms move into the newly refurbished Hayakawa Building. In the facility new occupiers CyanoCapture and... Read more

Ochre Bio Launches ‘Liver ICU’ in US to Evaluate Effects of RNA Therapies on Human Liver Performance

Ochre plans to maintain hundreds of discarded donor livers outside the body, mimicking human physiological conditions, to test the efficacy of new RNA therapeutics. Research is expected to advance the understanding of liver biology, with the goal of improving liver transplant outcomes and discovering novel therapies for liver diseases. Ochre announces partnerships with OrganOx, leaders in the field of liver perfusion technology, as well as... Read more

OrganOx announces partnership with Ochre Bio

OrganOx, a world leader in normothermic machine perfusion (NMP), today announced that it has partnered with Ochre Bio, a biotech company developing RNA medicines for chronic liver diseases. Under the terms of the partnership OrganOx will provide metra devices to Ochre Bio and its partners to evaluate the efficacy of novel RNA therapeutics using discarded donor livers perfused on the metra. Craig Marshall, OrganOx CEO, commented: “Thanks... Read more